Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

6.44
+0.650011.23%
Post-market: 6.690.2500+3.88%19:59 EDT
Volume:9.01M
Turnover:56.88M
Market Cap:53.15M
PE:-4.02
High:6.76
Open:5.74
Low:5.40
Close:5.79
Loading ...

CervoMed Says it Gets FDA's Orphan Drug Designation for Neflamapimod to Treat Frontotemporal Dementia

MT Newswires Live
·
27 Nov 2024

BRIEF-CervoMed's Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia

Reuters
·
27 Nov 2024

CervoMed Inc - to Report Topline Data From Phase 2B Dlb Trial in December 2024

THOMSON REUTERS
·
27 Nov 2024

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

THOMSON REUTERS
·
27 Nov 2024

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

GlobeNewswire
·
27 Nov 2024

North American Morning Briefing: Russia's Nuclear Doctrine News Triggers Risk-Aversion

Dow Jones
·
19 Nov 2024

CervoMed initiated with a Buy at D. Boral Capital

TIPRANKS
·
18 Nov 2024

CervoMed Is Maintained at Buy by Chardan Capital

Dow Jones
·
15 Nov 2024

BRIEF-CervoMed Announces Key Senior Leadership Appointments

Reuters
·
13 Nov 2024

CervoMed Announces Key Senior Leadership Appointments

THOMSON REUTERS
·
13 Nov 2024

Press Release: CervoMed Announces Key Senior Leadership Appointments

Dow Jones
·
13 Nov 2024

CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials

TIPRANKS
·
13 Nov 2024

CervoMed Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Sidoti Events, LLC's Virtual November Micro-Cap Conference

ACCESSWIRE
·
12 Nov 2024

CervoMed Q3 2024 GAAP EPS $(0.55) Misses $(0.38) Estimate, CervoMed Had Approximately $46.7M In Cash, Cash Equivalents And Marketable Securities, Expected To Provide Cash Runway Through 2025

Benzinga
·
12 Nov 2024

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire
·
12 Nov 2024